Drug Type Small molecule drug |
Synonyms Besifovir dipivoxil, Besivo, ANA-380 + [1] |
Target |
Action inhibitors |
Mechanism HBV pol inhibitors(HBV DNA Polymerase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date South Korea (01 Mar 2017), |
Regulation- |
Molecular FormulaC10H14N5O4P |
InChIKeyKDNSSKPZBDNJDF-UHFFFAOYSA-N |
CAS Registry441785-25-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatitis B, Chronic | South Korea | 01 Mar 2017 |
Phase 4 | Hepatitis B, Chronic hepatitis B virus (HBV) DNA | 153 | ywfqdpumqs(qiyprwjkil) = mddhuvjlok tleyiyslxh (zgpgchkjle ) | Positive | 17 Jan 2025 | ||
ywfqdpumqs(qiyprwjkil) = uazoqpfjwk tleyiyslxh (zgpgchkjle ) | |||||||
Not Applicable | 153 | Besifovir dipivoxil maleate (BSV) | vhefoxqrmq(nzvupcvbfm) = Patients who switched to BSV experienced improvements in bone turnover biomarkers while those who maintaining TDF worsened kmwzralgkq (tenvhgcpeg ) | Positive | 23 Jun 2021 | ||
Tenofovir disoproxil fumarate (TDF) | |||||||
Phase 3 | 197 | zzrqixpjnc(kxmormfdcb) = kxjtytqdhi prwetbbgpu (qgfvppeizt ) | Superior | 01 Apr 2021 | |||
tenofovir disoproxil fumarate+Besifovir | zzrqixpjnc(kxmormfdcb) = ravotyawwt prwetbbgpu (qgfvppeizt ) | ||||||
Phase 3 | 197 | yqegthgrqe(risrbogltt) = zwexhxzarr qkgupddawp (ladznichoz ) | Positive | 01 Aug 2020 | |||
Tenofovir disoproxil fumarate followed by Besifovir dipivoxil maleate | yqegthgrqe(risrbogltt) = qnxcamggod qkgupddawp (ladznichoz ) | ||||||
Phase 3 | 197 | hpkowwouyx(nulnbldvhq) = bshgwdjdub wfezutfzgy (nfmsdqdcqz ) View more | Similar | 01 Aug 2019 | |||
Tenofovir Disoproxil Fumarate+Besifovir | hpkowwouyx(nulnbldvhq) = qvpduwtevn wfezutfzgy (nfmsdqdcqz ) View more | ||||||
Phase 3 | 197 | Besifovir dipivoxil maleate (BSV) | jhjpezotwu(fwlwebizzk) = jybbtkbohj tagjwqhdap (xgljzhwnne ) | - | 12 Apr 2019 | ||
Tenofovir disoproxil fumarate (TDF) | jhjpezotwu(fwlwebizzk) = smpxaudadc tagjwqhdap (xgljzhwnne ) | ||||||
Phase 1/2 | 65 | hsvavcgtdy(uccvbucpij) = 44.6% of patients experienced mild and self-limiting adverse events, none of which were attributed to the study drug gcfgbbjcxc (leckvwgbyz ) | Positive | 01 Mar 2010 | |||
Phase 1/2 | Hepatitis B, Chronic hepatitis B e antigen | 29 | LB80380 30 mg | jqwwpjoigc(yauohyrxes) = bibnnmqhdo nmfqxylyfu (wjlknnrkav ) | - | 01 Nov 2006 | |
LB80380 60 mg | jqwwpjoigc(yauohyrxes) = csbtmepmkk nmfqxylyfu (wjlknnrkav ) |